Pawel Kalinski

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi IL-18-induced CD83+CCR7+ NK helper cells
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, PA, USA
    J Exp Med 202:941-53. 2005
  2. ncbi Generation of myeloid-derived suppressor cells using prostaglandin E2
    Natasa Obermajer
    Departments of Surgery, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA, 15213, USA
    Transplant Res 1:15. 2012
  3. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. ncbi Regulation of immune responses by prostaglandin E2
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Immunol 188:21-8. 2012
  5. ncbi Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:60. 2011
  6. ncbi Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4
    Pawel Kalinski
    University of Pittsburgh, Department of Surgery, The University of Pittsburgh Cancer Institute, Hillman Cancer Center, Suite 1 46, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 10:526-35. 2009
  7. ncbi Natural killer-dendritic cell cross-talk in cancer immunotherapy
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Expert Opin Biol Ther 5:1303-15. 2005
  8. ncbi Dendritic cell-based therapeutic cancer vaccines: what we have and what we need
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Res Pavilion, Suite 1 46, 5117 Center Avenue, PA 15213 1863, USA
    Future Oncol 5:379-90. 2009
  9. ncbi Helper role of NK cells during the induction of anticancer responses by dendritic cells
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Mol Immunol 42:535-9. 2005
  10. ncbi Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 36:137-46. 2006

Research Grants

  1. Polarization of Dendritic Cells by CD8 T cells
    Pawel Kalinski; Fiscal Year: 2006
  2. Polarized DC as Melanoma Vaccine: Phase 1 Evaluation
    Pawel Kalinski; Fiscal Year: 2006
  3. Regulation of DC Activity by Memory and Effector CD8+ T Cells
    Pawel Kalinski; Fiscal Year: 2010

Detail Information

Publications58

  1. ncbi IL-18-induced CD83+CCR7+ NK helper cells
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, PA, USA
    J Exp Med 202:941-53. 2005
    ..The current data demonstrate independent regulation of the "helper" versus "effector" pathways of NK cell differentiation and novel mechanisms of immunoregulation by IL-18 and PGE2...
  2. ncbi Generation of myeloid-derived suppressor cells using prostaglandin E2
    Natasa Obermajer
    Departments of Surgery, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA, 15213, USA
    Transplant Res 1:15. 2012
    ..Our observations provide a simple method for generating large numbers of MDSCs for the immunotherapy of autoimmune diseases, chronic inflammatory disorders and transplant rejection...
  3. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. ncbi Regulation of immune responses by prostaglandin E2
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Immunol 188:21-8. 2012
    ..Targeting the production, degradation, and responsiveness to PGE(2) provides tools to modulate the patterns of immunity in a wide range of diseases, from autoimmunity to cancer...
  5. ncbi Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer
    James M Balwit
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:60. 2011
    ....
  6. ncbi Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4
    Pawel Kalinski
    University of Pittsburgh, Department of Surgery, The University of Pittsburgh Cancer Institute, Hillman Cancer Center, Suite 1 46, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 10:526-35. 2009
    ....
  7. ncbi Natural killer-dendritic cell cross-talk in cancer immunotherapy
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Expert Opin Biol Ther 5:1303-15. 2005
    ..Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers...
  8. ncbi Dendritic cell-based therapeutic cancer vaccines: what we have and what we need
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Res Pavilion, Suite 1 46, 5117 Center Avenue, PA 15213 1863, USA
    Future Oncol 5:379-90. 2009
    ..Furthermore, recent studies also identify the tools to counteract such phenomena, in order to assure the desirable induction of Th1-cytotoxic T lymphocytes, NK-mediated type-1 immunity and appropriate homing of effector cells to tumors...
  9. ncbi Helper role of NK cells during the induction of anticancer responses by dendritic cells
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Mol Immunol 42:535-9. 2005
    ..We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma...
  10. ncbi Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 36:137-46. 2006
    ..The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy...
  11. ncbi Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses
    Pawel Kalinski
    Hillman Cancer Center, University of Pittsburgh Cancer Institute Research Pavilion, Room 1 46b, 5117 Center Avenue, Pittsburgh, PA 15213 1863, USA
    Nat Rev Immunol 5:251-60. 2005
    ....
  12. ncbi Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, United States
    Semin Immunol 22:173-82. 2010
    ..These developments allow for selective induction of tumor-specific T cells with desirable effector functions and tumor-relevant homing properties and to direct the desirable types of immune cells to tumors...
  13. ncbi Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 50:235-47. 2011
    ....
  14. ncbi 9th Annual Meeting of the Regional Cancer Consortium for the Biological Therapy of Cancer. 16-18 February 2006, UPMC Herberman Conference Center, Pittsburgh, PA, USA
    Pawel Kalinski
    Hillman Cancer Center, University of Pittsburgh, Cancer Institute, Pittsburgh, PA 15213-1863, USA
    Expert Opin Biol Ther 6:631-3. 2006
  15. ncbi Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners
    Xinmei Zhu
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 59:1401-9. 2010
    ..Our data point to critical roles of the host-IFN-alpha and IFN-gamma pathways in the modulation of CNS glioma microenvironment, and the therapeutic effectiveness of poly-ICLC-assisted glioma vaccines...
  16. ncbi Memory CD8+ T cells protect dendritic cells from CTL killing
    Payal B Watchmaker
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    J Immunol 180:3857-65. 2008
    ....
  17. ncbi Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells
    Payal B Watchmaker
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Immunol 184:591-7. 2010
    ....
  18. ncbi Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity
    Yutaro Nakamura
    Department of Surgery, University of Pittsburgh, Eye and Ear Institute, PA 15213 1863, USA
    Cancer Res 67:10012-8. 2007
    ....
  19. ncbi Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines
    Adam S Giermasz
    Department of Surgery, Hillman Cancer Center, University of Pittsburgh, UPCI Research Pavilion, Room 1 46b, 5117 Center Avenue, Pittsburgh, PA 15213 1863, USA
    Cancer Immunol Immunother 58:1329-36. 2009
    ..The current data help to explain the previously reported Th1-driving and anti-tumor activities of IL-4, and demonstrate that type-1 polarization increases in vivo activity of DC-based vaccines...
  20. ncbi Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Immunol 171:2366-73. 2003
    ..The currently demonstrated helper activity of NK cells may support the development of Th1- and CTL-dominated type 1 immunity against intracellular pathogens and may have implications for cancer immunotherapy...
  21. ncbi IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Immunother 32:793-802. 2009
    ..These data suggest that treatment strategies capable of sustaining/enhancing VLA-4/VLA-6 expression on Th1 effector cells may yield improved clinical efficacy in the cancer setting...
  22. ncbi PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells
    Ravikumar Muthuswamy
    Department of Surgery, University of Pittsburgh, PA 15213 1863, USA
    Blood 116:1454-9. 2010
    ..Our data help to explain the impact of PGE(2) on CCR7 expression in maturing DCs and demonstrate a novel mechanism of regulatory activity of PGE(2), mediated by the inhibition of DCs ability to attract naive T cells...
  23. ncbi alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-1863, USA
    Cancer Res 64:5934-7. 2004
    ..Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines...
  24. ncbi Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10
    Mitsugu Fujita
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 69:1587-95. 2009
    ..Collectively, these findings show the anti-CNS glioma effects of DC1-based therapy and a novel role of CXCL10 in the immunologic and therapeutic activity of DC-based cancer vaccines...
  25. ncbi Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells
    Jeffrey L Wong
    Department of Surgery, University of Pittsburgh, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 1863, USA
    J Immunother 34:270-8. 2011
    ..These results indicate that the helper function of NK cells can be used in clinical settings to improve the effectiveness of DC-based cancer vaccines...
  26. ncbi Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation
    Ravikumar Muthuswamy
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA
    Cancer Res 68:5972-8. 2008
    ....
  27. ncbi Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro
    Michael W Lipscomb
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 183:7250-8. 2009
    ..Tbets promote improved type 1 functional polarization from naive T cell responders. Given their superior type 1 polarizing capacity, DC.Tbet may be suitable for use in vaccines designed to prevent/treat cancer or infectious disease...
  28. ncbi Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in
    Hideho Okada
    G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    J Clin Oncol 29:330-6. 2011
    ..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100...
  29. ncbi Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function
    Andres Lopez-Albaitero
    Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Immunother 32:465-73. 2009
    ....
  30. ncbi Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking
    Brooke M Helfer
    Department of Research and Development, Celsense Inc, Pittsburgh, Pennsylvania, USA
    Cytotherapy 12:238-50. 2010
    ..We provide an assessment of this technology and examine its impact on the health and function of the DC...
  31. ncbi PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment
    Natasa Obermajer
    Department of Surgery, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 71:7463-70. 2011
    ..Together, our findings elucidate a central role for PGE(2) in MDSC accumulation triggered by the CXCL12-CXCR4 pathway, providing a powerful rationale to target PGE(2) signaling in ovarian cancer therapy...
  32. ncbi Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection
    Zheng Fan
    Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Clin Vaccine Immunol 14:1127-37. 2007
    ..DCs from these infected subjects have a normal capacity to stimulate CD4+ T cells. The functional effectiveness of DCs derived from HCV-infected individuals provides a rationale for the DC-based immunotherapy of chronic HCV infection...
  33. ncbi NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells
    Ravikumar Muthuswamy
    Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Cancer Res 72:3735-43. 2012
    ..Together, our findings suggest the feasibility of exploiting NF-κB hyperactivation in the tumor microenvironment to selectively enhance T(eff) entry into colon tumors...
  34. ncbi Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
    Je Jung Lee
    Department of Surgery and Medicine, University of Pittsburgh, University of Pittsburgh Cancer Institute, 1 46 Hillman Cancer Ctr, 5117 Centre Ave, Pittsburgh, PA 15213, USA
    J Leukoc Biol 84:319-25. 2008
    ..4-38 times) of functional CD8+ T cells against CLL cells. The current demonstration that autologous tumor-loaded alphaDC1 are potent inducers of CLL-specific T cells helps to develop improved immunotherapies of CLL...
  35. ncbi Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Methods Mol Biol 595:117-33. 2010
    ....
  36. ncbi Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells
    Natasa Obermajer
    Department of Surgery, University of Pittsburgh, Hillman Cancer Center, UPCI Research Pavilion, 5117 Center Ave, Pittsburgh, PA 15213 1863, USA
    Blood 118:5498-505. 2011
    ..The central role of COX2-PGE(2) feedback in the induction and persistence of MDSCs highlights the potential for its manipulation to enhance or suppress immune responses in cancer, autoimmunity, or transplantation...
  37. ncbi Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
    ....
  38. ncbi Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs
    Erik Berk
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Vaccine 30:6216-24. 2012
    ..These results demonstrate the feasibility of generation of polarized DC1s using autologous lymphocytes...
  39. ncbi Cytolytic cells induce HMGB1 release from melanoma cell lines
    Norimasa Ito
    Department of Surgery, University of Pittsburgh School of Medicine, Hillman Cancer Center, 5117 Centre Avenue, Room G 21, Pittsburgh, PA 15213, USA
    J Leukoc Biol 81:75-83. 2007
    ..Specifically, HMGB1 may promote healing or immune reactivity, depending on the nature of the local inflammatory response and the presence (or absence) of immune effectors...
  40. ncbi Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses
    Robbie B Mailliard
    Department of Surgery, Cancer Institute, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15261, USA
    J Exp Med 195:473-83. 2002
    ....
  41. ncbi Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes
    Eva Wieckowski
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Prostate 71:125-33. 2011
    ....
  42. ncbi Generation of human type 1- and type 2-polarized dendritic cells from peripheral blood
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, PA, USA
    Methods Mol Biol 215:427-36. 2003
  43. ncbi Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity
    Jun Li
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Neoplasia 14:1115-21. 2012
    ..This approach therefore represents a means to increase the safety and therapeutic benefit of oncolytic viruses, used alone or in combination with immune cell therapies...
  44. ncbi Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes
    Brian S Sheridan
    Graduate Program in Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Virol 83:2237-45. 2009
    ..Identification of the viral proteins recognized by these cells will contribute to a better understanding of the dynamics of HSV-1 latency...
  45. ncbi Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity
    Young-Ik Son
    Department of Surgery, University of Pittsburgh, Hillman Cancer Center Research Pavilion, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, USA
    Eur J Immunol 33:2007-13. 2003
    ....
  46. ncbi Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer
    Jun Li
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Mol Ther 19:650-7. 2011
    ..This approach therefore represents a novel means of combining biological therapies for cancer treatment...
  47. ncbi IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination
    Radha Gopal
    Division of Infectious Diseases, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA
    Eur J Immunol 42:364-73. 2012
    ....
  48. ncbi Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Transl Med 5:67. 2007
    ..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts...
  49. ncbi Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens
    Xi Zhao
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Mol Ther 19:805-14. 2011
    ..These TASA and their derivative peptides may prove useful in vaccine formulations against solid cancers, as well as, in the immune monitoring of HLA-A2(+) cancer patients receiving therapeutic interventions, such as IL-12 gene therapy...
  50. ncbi Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
    Amy Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, PA 1513, USA
    J Immunother 30:75-82. 2007
    ..These results suggest that preexisting CD4+ T cell immunity to cancer is not relegated to Type-1 insufficiency and may be corrected via the application of DC1-based vaccination protocols...
  51. ncbi Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA
    J Immunother 35:702-10. 2012
    ..T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg...
  52. ncbi Zinc in innate and adaptive tumor immunity
    Erica John
    Department of Surgery, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Transl Med 8:118. 2010
    ..Based on this novel synthesis, approaches which locally regulate zinc levels to promote survival of immune cells and/or induce tumor apoptosis are in order...
  53. ncbi Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II
    Anna E Lokshin
    Department of Obstetrics Gynecology and Reproductive Sciences, University of Pittsburgh, PA 15213, USA
    Int Immunol 14:1027-37. 2002
    ..This opens the possibility of differential regulation of each of these events in immunotherapy...
  54. ncbi A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells
    Young-Ik Son
    Department of Surgery, Division of Surgical Oncology/Biological Therapeutics, University of Pittsburgh Cancer Institute, W1540, Biomedical Science Tower, 200 Lothrop Street, PA 15261, USA
    J Immunol Methods 262:145-57. 2002
    ..These data indicate that bulk-DC are functionally more mature than conventional DC. Taken together, bulk-culture method is a simple technique for generating functionally mature BM-DC in large quantities and high purity...
  55. ncbi The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells
    Philip J Vernon
    Department of Surgery, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15219, USA
    J Immunol 190:1372-9. 2013
    ..KCR mice also maintained a significantly less suppressive milieu evidenced by marked decreases in CCL22 in relation to CXCL10 and diminished serum levels of IL-6...
  56. ncbi Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA
    Naoki Umemura
    Cancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 72:45-55. 2012
    ..By elucidating how TLR3 ligands trigger apoptosis in metastatic cells, our findings suggest insights into how to improve their clinical use...
  57. ncbi Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18
    M Cristina Lebre
    Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Invest Dermatol 120:990-7. 2003
    ....
  58. ncbi Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals
    Esther C de Jong
    Department of Cell Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 168:1704-9. 2002
    ..The data suggest that the molecular basis of Th1/Th2 polarization via DCs is unexpectedly diverse and is adapted to the nature of the microbial compounds...

Research Grants10

  1. Polarization of Dendritic Cells by CD8 T cells
    Pawel Kalinski; Fiscal Year: 2006
    ..abstract_text> ..
  2. Polarized DC as Melanoma Vaccine: Phase 1 Evaluation
    Pawel Kalinski; Fiscal Year: 2006
    ....
  3. Regulation of DC Activity by Memory and Effector CD8+ T Cells
    Pawel Kalinski; Fiscal Year: 2010
    ..abstract_text> ..